Pdt Partners, LLC Aerie Pharmaceuticals Inc Transaction History

Pdt Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $617,081 - $1.48 Million	-96,873 Reduced 61.69%	60,164 $910,000
Q2 2022 Aug 15, 2022	SELL	$4.95 - $9.16 $19,196 - $35,522	-3,878 Reduced 2.41%	157,037 $1.18 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $679,608 - $1.18 Million	120,498 Added 298.14%	160,915 $1.46 Million
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $283,727 - $538,758	40,417 New	40,417 $284,000
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $1.05 Million - $1.55 Million	-93,136 Closed	0 $0

Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $469,853 - $587,937	30,993 Added 49.87%	93,136 $1.49 Million
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $24,495 - $39,020	-1,867 Reduced 2.92%	62,143 $1.11 Million
Q4 2020 Feb 16, 2021	BUY	$9.12 - $14.49 $583,771 - $927,504	64,010 New	64,010 $865,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.